In the same RCC model, the addition of anti-PD-L1 to a bevacizumab-like agent in the adjuvant setting did not yield similar combination activity, while the sunitinib plus anti-PD-L1 combination became ineffective when administered as early therapy for unresected primary tumours or late-stage therapy for advanced metastatic disease. This evidence concerns the gene CD274 and neoplasm.